Cargando…

Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B

AIMS: Assessing the diagnostic performances of APRI and FIB-4 using age as a categorical marker. METHODS: 822 chronic hepatitis B (CHB) patients were included. Using METAVIR scoring system as a reference, the performances of APRI and FIB-4 were compared between patients aged≥30 and patients aged<...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qiang, Lu, Chuan, Li, Weixia, Huang, Yuxian, Chen, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542225/
https://www.ncbi.nlm.nih.gov/pubmed/28514753
http://dx.doi.org/10.18632/oncotarget.17470
_version_ 1783254946538323968
author Li, Qiang
Lu, Chuan
Li, Weixia
Huang, Yuxian
Chen, Liang
author_facet Li, Qiang
Lu, Chuan
Li, Weixia
Huang, Yuxian
Chen, Liang
author_sort Li, Qiang
collection PubMed
description AIMS: Assessing the diagnostic performances of APRI and FIB-4 using age as a categorical marker. METHODS: 822 chronic hepatitis B (CHB) patients were included. Using METAVIR scoring system as a reference, the performances of APRI and FIB-4 were compared between patients aged≥30 and patients aged<30 years. RESULTS: The APRI AUROC in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (0.61 vs 0.70, p<0.001) and cirrhosis (0.64 vs 0.78, p<0.001). The FIB-4 AUROC in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (0.57 vs 0.65, p<0.001) and cirrhosis (0.63 vs 0.72, p<0.001). Using specificity≥90%, the APRI cut-off in patients aged<30 years was lower than patients aged≥30 years for significant fibrosis (1.0 vs 1.2) and cirrhosis (1.2 vs 1.5). Using sensitivity≥90%, the APRI cut-off in patients aged<30 years was also lower than patients aged≥30 years for significant fibrosis (0.2 vs 0.4) and cirrhosis (0.3 vs 0.5). Using specificity≥90%, the FIB-4 cut-off in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (1.2 vs 2.1) and cirrhosis (1.4 vs 2.6). Using sensitivity≥90%, the FIB-4 cut-off in patients aged<30 years was also lower than that in patients aged≥30 years for significant fibrosis (0.5 vs 0.8) and cirrhosis (0.8 vs 1.2). CONCLUSIONS: Evaluation of the diagnostic performances of APRI and FIB-4 should take age into consideration.
format Online
Article
Text
id pubmed-5542225
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55422252017-08-07 Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B Li, Qiang Lu, Chuan Li, Weixia Huang, Yuxian Chen, Liang Oncotarget Research Paper AIMS: Assessing the diagnostic performances of APRI and FIB-4 using age as a categorical marker. METHODS: 822 chronic hepatitis B (CHB) patients were included. Using METAVIR scoring system as a reference, the performances of APRI and FIB-4 were compared between patients aged≥30 and patients aged<30 years. RESULTS: The APRI AUROC in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (0.61 vs 0.70, p<0.001) and cirrhosis (0.64 vs 0.78, p<0.001). The FIB-4 AUROC in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (0.57 vs 0.65, p<0.001) and cirrhosis (0.63 vs 0.72, p<0.001). Using specificity≥90%, the APRI cut-off in patients aged<30 years was lower than patients aged≥30 years for significant fibrosis (1.0 vs 1.2) and cirrhosis (1.2 vs 1.5). Using sensitivity≥90%, the APRI cut-off in patients aged<30 years was also lower than patients aged≥30 years for significant fibrosis (0.2 vs 0.4) and cirrhosis (0.3 vs 0.5). Using specificity≥90%, the FIB-4 cut-off in patients aged<30 years was lower than that in patients aged≥30 years for significant fibrosis (1.2 vs 2.1) and cirrhosis (1.4 vs 2.6). Using sensitivity≥90%, the FIB-4 cut-off in patients aged<30 years was also lower than that in patients aged≥30 years for significant fibrosis (0.5 vs 0.8) and cirrhosis (0.8 vs 1.2). CONCLUSIONS: Evaluation of the diagnostic performances of APRI and FIB-4 should take age into consideration. Impact Journals LLC 2017-04-27 /pmc/articles/PMC5542225/ /pubmed/28514753 http://dx.doi.org/10.18632/oncotarget.17470 Text en Copyright: © 2017 Li et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Li, Qiang
Lu, Chuan
Li, Weixia
Huang, Yuxian
Chen, Liang
Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B
title Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B
title_full Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B
title_fullStr Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B
title_full_unstemmed Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B
title_short Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B
title_sort impact of age on the diagnostic performances and cut-offs of apri and fib-4 for significant fibrosis and cirrhosis in chronic hepatitis b
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542225/
https://www.ncbi.nlm.nih.gov/pubmed/28514753
http://dx.doi.org/10.18632/oncotarget.17470
work_keys_str_mv AT liqiang impactofageonthediagnosticperformancesandcutoffsofapriandfib4forsignificantfibrosisandcirrhosisinchronichepatitisb
AT luchuan impactofageonthediagnosticperformancesandcutoffsofapriandfib4forsignificantfibrosisandcirrhosisinchronichepatitisb
AT liweixia impactofageonthediagnosticperformancesandcutoffsofapriandfib4forsignificantfibrosisandcirrhosisinchronichepatitisb
AT huangyuxian impactofageonthediagnosticperformancesandcutoffsofapriandfib4forsignificantfibrosisandcirrhosisinchronichepatitisb
AT chenliang impactofageonthediagnosticperformancesandcutoffsofapriandfib4forsignificantfibrosisandcirrhosisinchronichepatitisb